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Eradication rates of Helicobacter pylori following standard triple therapy are declining 
worldwide, but high-dose proton-pump inhibitor-based triple therapy (HD-PPI-TT) and 
sequential therapy (ST) have demonstrated higher cure rates. We aimed to compare the efficacy 
and tolerability of HD-PPI-TT and ST in H. pylori-associated functional dyspepsia (HP-FD). 
Methods 
One hundred and twenty HP-FD patients were randomized to receive 10-day HD-PPI-TT (60 mg 
lansoprazole/500 mg clarithromycin/1 g amoxicillin, each administered twice daily for 10 days) 
or 10-day ST (30 mg lansoprazole/1 g amoxicillin, each administered twice daily for 5 days 
followed by 30 mg lansoprazole/500 mg clarithromycin/400 mg metronidazole, each 
administered twice daily for 5 days). H. pylori status was determined in post-treatment week 4 
by 14C-urea breath test. Eradication and antibiotic resistance rates, dyspeptic symptoms, drug 
compliance, and adverse effects were compared. 
Results  
Intention-to-treat (ITT) eradication rates were similar in the ST and HD-PPI-TT groups (85% vs. 
80%; P=0.47). However, the eradication rate was significantly higher following ST compared 
with HD-PPI-TT in per protocol (PP) analysis (94.4% vs. 81.4%; P=0.035). ST achieved higher 
cure rates than HD-PPI-TT in clarithromycin-resistant H. pylori strains (100% vs. 33.3%; 
P=0.02). Treatment compliance was similar in the HD-PPI-TT and ST groups, although nausea 
and dizziness were more common in the ST group. 
Conclusions 
ST achieved better H. pylori eradication than HD-PPI-TT in patients with FD. However, the 
eradication rate for ST fell from 94.4% in PP to 85% in ITT analysis. Adverse effects might 
result in poorer compliance and compromise actual ST efficacy. (ClinicalTrials.gov: 
NCT01888237). 
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INTRODUCTION 
Helicobacter pylori plays an important role in the pathogenesis of chronic gastritis, peptic ulcer, 
and gastric cancer, and its successful eradication alters the natural history of these conditions.1, 2 
Both the Thai and Second Asia-Pacific Consensus Guidelines for H. pylori 2009 currently 
recommend proton-pump inhibitor-(PPI) based triple therapy (TT), referred to as standard TT 
(standard dose PPI + clarithromycin + amoxicillin or metronidazole), as frontline treatment for 
H. pylori eradication.3, 4 However, the efficacy of this regimen has reportedly decreased to 50%–
75% worldwide, with clarithromycin-resistance recognized as a major cause of this treatment 
failure.5, 6 
Sequential therapy (ST), consisting of standard-dose PPI + amoxicillin for the first 5 days 
followed by 5 additional days of PPI + clarithromycin + metronidazole, reportedly increases the 
efficacy of H. pylori eradication and is now recommended as the first-line regimen in some 
guidelines.3, 4, 7, 8 A recent meta-analysis revealed that ST achieved a higher eradication rate than 
standard TT,9 with eradication rates of up to 95% reported for ST in Thailand.10 However, ST is 
a complicated regimen compared with TT, with implications for patient compliance and 
facilitating the development of drug resistance.11  
Evidence suggests that a sustained higher intragastric pH is a major therapeutic determinant of 
H. pylori eradication.12 Other factors, including inflammatory cytokine polymorphisms, 
especially the interleukin-1B-511 T/T genotype which is responsible for more rapid PPI 
metabolism, can also negatively affect eradication rates.13 Higher doses of PPIs have thus been 
advocated in the hope of maximizing H. pylori eradication. A recent meta-analysis showed that 
high-dose PPI triple therapy (HD-PPI-TT) eradicated H. pylori more effectively than TT with 
standard doses of PPI.14 Moreover, Vilaichone et al. reported that 14-day HD-PPI-TT achieved 
an excellent cure rate of up to 100%, regardless of the CYP2C19 genotype.15 These findings, 
together with the fact that the regimen is simpler and more familiar to physicians than ST, make 
HD-PPI-TT an attractive therapeutic option. 
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This study aimed to compare the efficacies of ST and HD-PPI-TT in patients with H. pylori -
associated functional dyspepsia. We hypothesized that both regimens would show comparable 
efficacies for eradicating H. pylori. Secondary outcomes included changes in dyspeptic symptom 
scores at 4, 8, and 24 weeks, compliance rates, adverse events, and the prevalence of 
clarithromycin-resistant H. pylori. 
METHODS 
Design overview 
This was a prospective, randomized, controlled, open-label study including consecutive patients 
who met the inclusion and exclusion criteria. All participants provided written informed consent 
and were randomly assigned to one of two treatment groups. Follow-up visits were scheduled 4 
weeks after completing treatment to determine eradication rates, treatment compliance, and the 
incidence of adverse events. The study was approved by the ethics committees of the 
participating center. (ClinicalTrials.gov: NCT01888237). 
Patients  
Consecutive patients attending a tertiary care hospital in Bangkok, Thailand, between May 2013 
and March 2014 with functional dyspepsia, including epigastric pain and post-prandial distress 
syndrome, defined by the Rome III criteria, were enrolled. All patients who presented with at 
least one of four cardinal dyspepsia symptoms (postprandial fullness, early satiation, epigastric 
pain, and epigastric burning) were recruited.16 Eligible patients had compatible symptoms and 
had undergone esophagogastroduodenoscopy (EGD) with no evidence of peptic ulcer disease, 
gastric cancer, or erosive esophagitis. All patients had active H. pylori infection documented by a 
positive rapid urease test. Patients were at least 18 years old and had not previously been treated 
for H. pylori infection. PPIs or histamine H2 receptor antagonists were withheld for at least 2 
weeks prior to EGD. Exclusion criteria were: (i) use of non-steroidal anti-inflammatory drugs or 
antibiotics within the 2 weeks prior to EGD; (ii) current use of anticoagulants or ketoconazole; 
(iii) contraindication(s) to gastric biopsy; (iv) history of gastric surgery; (v) severe or unstable 
cardiovascular, pulmonary, or endocrine disease; clinically significant renal or hepatic disease or 
dysfunction; hematological disorders; AIDS; stroke (bed ridden); (vi) pregnancy or lactation; and 
(vii) allergy to any of the study drugs. 
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Randomization and interventions 
Patient allocation was performed using a computer-generated randomization chart. Patients were 
randomly allocated to receive a 10-day course of HD-PPI-TT (60 mg lansoprazole, 500 mg 
clarithromycin, and 1 g amoxicillin, each administered twice daily for 10 days) or a 10-day 
course of ST (30 mg lansoprazole, 1 g amoxicillin, each administered twice daily for the first 5 
days, followed by 30 mg lansoprazole, 500 mg clarithromycin, and 400 mg metronidazole, each 
administered twice daily for the remaining 5 days). The required medications were supplied in 
individual blister packs with detailed instructions on how to take them. 
Measurements and outcomes 
The primary outcome of the study was comparative H. pylori eradication rates in patients 
receiving ST and HD-PPI-TT regimens. Secondary outcomes were adherence and adverse events 
in the two study groups. The impact of clarithromycin resistance on eradication rates of ST and 
HD-PPI-TT was also assessed.17 Notably, we did not collect data on metronidazole or 
amoxicillin resistance. Dyspeptic symptoms were assessed in all participants before and 6 
months after treatment of H. pylori by face to face interviews in our hospital clinic, or by phone 
interview in patients unable to attend a meeting. A modified SF-Leeds dyspepsia score was used 
to evaluate upper gastrointestinal symptoms at baseline, and at weeks 4, 8, and 24 after 
completion of treatment.18 Symptoms assessed included epigastric pain/discomfort, heartburn, 
acid regurgitation, and nausea and vomiting. Symptom severity was scored from 0 (no 
symptoms) to 4 (more than once a day). 
14C-Urea breath test 
Urease activity was detected as a surrogate marker of H. pylori infection by 14C-urea breath test 
using a PYtest kit (Kimberley-Clark, Roswell, GA, USA) and a Microcount scintillation counter 
(Halyard Health, Alpharetta, GA, USA). After at least 6 h fasting, participants were asked to 
ingest a PYtest 14C-labeled urea capsule with 30 mL of water, followed by an additional 20 mL 
of water 3 min later. Single-breath samples were then collected 7 min later by exhaling into 
Mylar breath-collection balloons after holding their breath for 5–10 s. The amount of 14C in the 
balloon was measured using a scintillation counter and reported as disintegrations per minute 
(DPM). Participants were classified as negative (uninfected) if their DPM value was <50. 
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Endoscopy and H. pylori detection 
All eligible participants underwent EGD during which gastric biopsies were collected from the 
antrum and incisura, respectively, and used for the rapid urease test (Kimberly-Clark). An 
additional five biopsy specimens were collected from each patient, including two from the 
antrum, two from the corpus, and one from the incisura, placed into sterile bottles and sent to the 
Department of Microbiology, Faculty of Medicine, Siriraj Hospital for culture. Patients with a 
positive rapid urease test were invited to participate in the study. 
For bacterial culture and susceptibility testing, biopsy specimens were delivered directly to a 
single microbiological laboratory within 2 h of biopsy and then stored at −70°C. Isolated strains 
were obtained using Columbia or sheep blood agar in a microaerophilic environment and tested 
for primary clarithromycin resistance using the Epsilometer test (BioMérieux, Durham, NC, 
USA). The results were considered positive if the minimal inhibitory concentration was >1 
mg/L. 
Follow-up procedures 
Compliance with treatment and adverse events 
Patients were scheduled for follow-up visits to assess symptoms, compliance with therapy, and 
adverse events. Adverse events were evaluated by asking open-ended questions, followed by 
more specific questions relating to anticipated adverse effects. Compliance was pre-defined as 
the consumption of >90% of the prescribed drugs and was determined by pill counts.  
Confirmation of eradication 
14C-urea breath tests were performed at least 4 weeks after completion of treatment and infection 
was considered to have been eradicated when the result was <50 DPM. 
Statistical analysis 
We calculated the sample size needed to detect a difference in eradication rates between ST 
(assumed to have an eradication rate of 97%) and HD-PPI-TT (assumed to have an eradication 
rate of 82%) of 15%, with power of 80% and significance level of 0.05 (alpha = 0.05, two-
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sided).8, 14 A 10% dropout rate was anticipated. The minimum required sample size was 
calculated to be 59 patients per group. 
The primary study outcome was a comparison of H. pylori eradication rates between the ST and 
HD-PPI-TT regimens using the intention to treat (ITT) population. A secondary per protocol 
(PP) analysis was also performed. Categorical variables were reported as numbers and 
percentages. Eradication rates were compared between the groups using χ2 and Fisher’s exact 
tests. The 95% confidence intervals for the eradication rate ratio and difference in absolute risk 
between the two groups were calculated. The secondary outcome was the impact of 
clarithromycin resistance on eradication rates, and adherence and adverse events were reported 
as numbers and percentages and compared between the ST and HD-PPI-TT groups using χ2 and 
Fisher’s exact tests. The composite dyspepsia scores at each time point from baseline to 24 
weeks after treatment were compared using Student’s t-tests. All statistical analyses were 
performed using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA). A P value < 0.05 was 
considered statistically significant. 
RESULTS 
Study population  
The patient flow chart is shown in Figure 1. The mean patient age (± standard deviation) was 
49.6±11.1 years. The baseline characteristics of the patients were similar in both groups (Table 
1). Among the 120 randomly assigned patients, seven were excluded from the PP analysis, 
including one in the HD-PPI-TT group because of adverse events and six in the ST group 
because of loss to follow-up (n=2) and adverse events (n=4). Sixty patients in the HD-PPI-TT 
and 60 in the ST group were finally included in the ITT analysis, and 59 patients in the HD-PPI-
TT and 54 in the ST group were available for PP analysis. More patients were excluded from the 
ST than the HD-PPI-TT group, but the difference was not significant (6/60 = 10% and 1/60 = 
1.67%, respectively; P = 0.11). 
Eradication of H. pylori infection 
The overall eradication rates of the two treatments according to ITT and PP are summarized in 
Table 2. The eradication rates were 80% in the HD-PPI-TT group and 85% in the ST group (P = 
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0.47) according to primary ITT analysis, and 81.4% and 94.4%, respectively, according to PP 
analysis (P = 0.035).  
Role of clarithromycin resistance in eradication of H. pylori infection 
Ninety of the 120 study subjects (75%) had positive H. pylori cultures, with similar proportions 
in both treatment groups (48/60 [80%] in the HD-PPI-TT and 42/60 [70%] in the ST group; P = 
0.21). Nine of the 90 patients (10%) had clarithromycin-resistant strains of H. pylori. The 
eradication rates of the two treatments stratified by clarithromycin resistance are shown in Table 
3. Clarithromycin-resistant H. pylori was eradicated in one of three (33.3%) patients treated with 
HD-PPI-TT versus six out of six (100%) treated with ST (P = 0.02). The eradication rates in 
patients with clarithromycin-susceptible H. pylori strains were similar for both treatments 
(86.7% vs. 83.3% for HD-PPI-TT and ST, respectively; P = 0.68). 
Treatment compliance  
A total of 59/60 patients (98.3%) in the HD-PPI-TT and 54/58 (93.1%) in the ST group complied 
with the allocated treatment (>90% of medication taken according to pill count). There was no 
significant difference in compliance between the groups (P = 0.20). 
Adverse events 
There was no significant difference in the incidence of adverse events reported by the two 
treatment groups, (P = 0.20) (Table 4). However, there was a tendency towards a higher rate of 
adverse events in the ST group, with taste disturbance, dry mouth, and nausea being the most 
commonly reported events. The most common adverse events in the HD-PPI-TT group were 
taste disturbance, dry mouth, and abdominal bloating. Four patients in the ST and one in the HD-
PPI-TT group discontinued treatment because of adverse events including taste disturbance, 
dizziness, nausea, and vomiting. All patients in the ST group who discontinued their medication 
did so during the last 5 days, when they were taking metronidazole and clarithromycin.  
Dyspeptic symptoms 
The median composite dyspepsia scores decreased gradually over time in both groups (P < 
0.001), with no significant differences in scores between the two groups (ITT analysis: Figure 
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2A, PP analysis: Figure 2B). Furthermore, this pattern was similar in patients with and without 
successful H. pylori eradication (Figure 3). 
DISCUSSION 
Many guidelines currently recommend standard TT as the first-line treatment for eradication of 
H. pylori infection.4, 8, 19 Although early studies of first-line standard TT demonstrated 
eradication rates of >85%,20 a meta-analysis suggested that the current eradication rate is likely 
to be <80%,21 with increased antibiotic resistance, particularly to clarithromycin, being 
responsible for this decline.5 Reported rates of clarithromycin resistance in Thailand have ranged 
from 3.5%–23% over the past 13 years. The current study, conducted in a tertiary care facility, 
identified a 10% prevalence of clarithromycin resistance amongst H. pylori strains. 
ST has proven superior to 7–10 days of standard TT for eradicating H. pylori.8, 22-25 It has been 
suggested that H. pylori can develop efflux channels to remove clarithromycin rapidly from the 
bacterial cell.26 Given that amoxicillin acts on and weakens the bacterial cell wall, it is possible 
that this initial phase of treatment may prevent the development of efflux channels, thus 
improving the efficacy of clarithromycin in the second phase of treatment.26 It is also possible 
that the efficacy of ST may be related to the use of three, rather than two antibiotics.27 However, 
the increased complexity of ST and consequently negative effects on compliance are potential 
concerns of this type of regimen.11  
A meta-analysis of large, multicenter, randomized trials found that HD-PPI-TT was more 
efficacious than standard TT.14 Sugimoto et al. reported that cure rates were closely related to the 
degree of acid inhibition, with a mean gastric pH of 6.4 in patients with H. pylori eradication 
compared with 5.2 in those in those without eradication.12 Moreover, differences in CYP2C19 
genotypes and the associated effects on PPI metabolism may affect the potency of acid 
inhibition.28, 29 However, methods for determining CYP2C19 genotype are not widely available, 
and the use of HD-PPI-TT offers a practical way of circumventing this issue. 
Studies directly comparing HD-PPI-TT and ST are lacking, and the current study was the first 
prospective, randomized, controlled, open-label study to compare these two regimens in patients 
with H. pylori -positive functional dyspepsia. The eradication rates of the two regimens were 
similar according to primary ITT analysis (80% HD-PPI-TT, 85% ST; P=0.47), but ST achieved 
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a significantly higher eradication rate than HD-PPI-TT according to PP analysis (94.4% vs. 
81.4%, P=0.035) (Table 2). The eradication rates in our study were similar to those reported in 
recent meta-analyses (97% and 82% for ST and HD-PPI-TT, respectively).14, 30 However, the 
eradication rate of 80% for HD-PPI-TT differed from that reported by Vilaichone et al., who 
found an eradication rate of 100% with this regimen.15 There are several possible explanations 
for these divergent eradication rates: firstly, our population had higher clarithromycin resistance 
(10% compared with 0%), and secondly, the duration of HD-PPI-TT was different (10 days in 
our study and 14 days in Vilaichone et al.).  
Among the small subgroup of patients with clarithromycin-resistant H. pylori, the eradication 
rate was significantly lower in the HD-PPI-TT compared with the ST group (33% vs. 100%, 
respectively; P = 0.02). These results are similar to those of other studies that reported greater 
efficacy of ST compared with TT in patients with clarithromycin-resistant H. pylori.8, 31 
However, given the small number of patients with clarithromycin-resistant H. pylori in this study 
we believe that it is premature to conclude that ST was superior to HD-PPI-TT based on the 
current data. Based on these observations, ST has been suggested as the optimal first-line therapy 
in regions with a prevalence of clarithromycin resistance >15%.32 
The current results regarding antimicrobial resistance should be interpreted with caution. The 
inability to culture H. pylori meant that complete antibiotic sensitivity tests were only carried out 
in 25% of patients, and the fact that only clarithromycin resistance was tested for in all patients 
thus limits the conclusions that can be drawn from this analysis. In particular, the failure to 
assess metronidazole resistance may be particularly important, given that metronidazole 
resistance has previously been shown to adversely affect the efficacy of sequential therapy.33 
Nevertheless, the relatively high rate of eradication by ST (85%) suggests that either there was a 
low rate of metronidazole resistance in the study population, or that metronidazole resistance had 
little effect on the efficacy of ST. 
The current study included 11 patients in the HD-PPI-TT group and three in the ST group who 
did not achieve successful eradication of H. pylori infection. Although two patients with 
treatment failure in the HD-PPI-TT group had clarithromycin-resistant H. pylori, treatment also 
failed in nine patients in the HD-PPI-TT and three in the ST group, despite the absence of 
clarithromycin resistance. This might be explained by amoxicillin or metronidazole resistance, 
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which was not assessed as part of this study. Our results thus suggest that the ability of ST to 
eradicate H. pylori was not substantively affected by clarithromycin resistance. The reason for 
this observation is unclear, but it is consistent with previous reports from other parts of the 
world.34, 35 
Poor compliance is the second most important reason after clarithromycin resistance for a failure 
to eradicate H. pylori.36 In a pooled-data analysis, Zullo et al. found no difference in compliance 
between ST and standard TT37 while another meta-analysis found no difference in compliance 
between HD-PPI-TT and standard TT.14 In our study, 98.3% of patients in the HD-PPI-TT and 
93.1% in the ST group complied with the treatment, which was consistent with these previous 
studies. 
Notably, this was the first study to compare HD-PPI-TT and ST directly. Although the overall 
incidence of adverse events did not differ significantly between the two regimens (P = 0.06), 
there was a trend towards a higher incidence of adverse events and discontinuations in the ST 
group.  
Whether or not H. pylori eradication improves functional dyspepsia remains controversial, 
though recent meta-analyses suggested a small but statistically significant benefit.38-40 The 
current study found that participants experienced a reduction in dyspeptic symptoms, measured 
by composite dyspepsia scores, at each time point between baseline and 24 weeks, regardless of 
whether their H. pylori was eradicated or not. However, the very small number of patients with 
persistent H. pylori infection following eradication therapy meant that it was not possible to 
make meaningful between-group comparisons. 
This study had several limitations. Firstly, the study was not blinded to patients or providers, 
creating the possibility of bias. Secondly, very few patients had clarithromycin-resistant H. 
pylori, and the results of this secondary analysis should thus be interpreted with caution. We did 
not test for amoxicillin or metronidazole resistance, and we were therefore unable to assess the 
potential impacts of these on the efficacies of the treatments. Furthermore, we did not analyze 
CYP2C19 genotypes, which could have been particularly relevant to the results for the HD-PPI-
TT group. Finally, it would have been interesting to include a treatment arm with a potassium-
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competitive acid blocker, which has recently been approved as part of a triple therapy regimen 
for first-line HP eradication in Japan.41  
In conclusion, we report the first randomized trial comparing the efficacy of HD-PPI-TT and ST 
in patients with HP-positive functional dyspepsia. Although the regimens showed similar 
efficacy according to ITT analysis, ST achieved higher eradication rates than HD-PPI-TT 
amongst patients who completed the prescribed treatment. ST may also offer incremental 
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Figure 2 Composite dyspepsia scores at each time point from baseline to 24 weeks after treatment; 
ITT analysis (A) and PP analysis (B) 
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Figure 3 Composite dyspepsia scores at each time point from baseline to 24 weeks after treatment 
in patients with successful and failed Helicobacter pylori (HP) eradication 
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Table 1 Baseline characteristics of the study population 
Variable HD-PPI-TT (n = 60) ST (n = 60) P value 
Mean age (SD), years 54.3 (11.9) 55.4 (14.1) 0.63 
Patients, n (%)    
 Men 28 (46.7) 18 (30.0) 0.06 
 Women 32 (53.3) 42 (70) 
Mean body mass index, kg/m2 24.0 24.9 0.24 
Patients who smoke, n (%) 14 (23.3) 7 (11.7) 0.10 
Patients who drink alcohol, n (%) 23 (38.3) 14 (23.3) 0.08 
H. pylori-positive culture, n (%) 48 (80) 42 (70) 0.21 
HD-PPI-TT, high-dose proton pump inhibitor-based triple therapy; ST, sequential therapy. 
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Table 2 Helicobacter pylori eradication rates in high-dose proton pump inhibitor based triple 
therapy (HD-PPI-TT) and sequential therapy (ST) groups. 






 Patients, n 
Eradication 
rate, n (%) 
Patients, n 
Eradication 
rate, n (%) 
  
ITT 60 48 (80) 60 51 (85) 1.7 0.47 
PP 59 48 (81.4) 54 51 (94.4) 11.1 0.035 
ITT, intention-to-treat; PP, per-protocol analysis 
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Table 3 Effect of clarithromycin susceptibility on Helicobacter pylori eradication rates of both 
regimens (based on per-protocol analysis) 
Clarithromycin HD-PPI-TT, n/n (%) ST, n/n (%) P value 
Resistant 1/3 (33.3) 6/6 (100) 0.02 
Susceptible 39/45 (86.7) 30/36 (83.3) 0.68 
HD-PPI-TT, high-dose proton pump inhibitor-based triple therapy; ST, sequential therapy 
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Table 4 Adverse events for both treatment regimens 
Adverse event HD-PPI-TT (n = 60), n (%) ST (n = 58), n (%) P value* 
Abdominal bloating 9 (15) 6 (10.3) 0.45 
Dizziness 3 (5) 10 (17.2) 0.03 
Dry mouth 16 (26.7) 22 (37.9) 0.19 
Fatigue 5 (8.3) 8 (13.8) 0.34 
Headache 4 (6.7) 8 (13.8) 0.20 
Nausea 4 (6.7) 12 (20.7) 0.03 
Taste disturbance 33 (55) 37 (63.8) 0.33 
Total 38 (63.3) 46 (79.3) 0.06 
Drug withdrawal due to 
adverse events 
1 (1.7) 4 (6.9) 0.20 
*Only adverse effects with an incidence >5% were included in the table. 
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